At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 29 enrolled
Drug / intervention
Brensocatib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2a, Single-Blind, Placebo-Controlled, Parallel-Group Study to Assess Safety, Tolerability, and Pharmacokinetics of Brensocatib Tablets in Adults With Cystic Fibrosis
In Brief
A Phase 2 clinical trial evaluating Brensocatib and Placebo for Cystic Fibrosis. Completed, enrolled 29 participants across 14 sites.
Detailed Summary
The main objective of the study is to evaluate the pharmacokinetics of brensocatib in participants with cystic fibrosis following once daily oral administration of study drug and to evaluate the safety of brensocatib compared to placebo in participants with cystic fibrosis (CF) over the 4-week treatment period.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCystic Fibrosis
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20222023202420252026
First PostedOct 2021
Enrollment StartNov 2021
Primary CompletionNov 2022
TodayJul 2026
First PostedOct 25, 2021
Enrollment StartNov 30, 2021
Primary CompletionNov 1, 2022
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 4.7 years ago
Interventions
Brensocatibdrug
Oral tablet
Placebodrug
Oral tablet